Occurrence of Selected Generic Drugs 8

Project Title Occurrence of Selected Generic Drugs 8
Date Posted
Wednesday, July 17, 2013
Project ID
MSY3-STR112
Status
Complete
Deliverables
Description

Summary table assessment of the use of 21 selected generic drug products including, Rosiglitazone/metformin hydrochloride (HCL), Rosiglitazone/Glimperide, Varenicline Tartrate, Propoxyphene HCL, Alvimopan, Isotretinoin, Ambrisentan, Alosetron HCL, Sibutramine Hydrochloride, Metoclopramide HCL, Lenalidomide, Buprenorphine HCL/Noloxone HCL, Buprenorphine HCL, Nilotinib Hydrochloride, Thalidomide, Bosentan, Burpopion HCL, Ribavirin/interferon A-2B, Sacrosidase, Propoxyphene HCL/Acetaminophen, and Propoxyphene HCL/ASA/Caffeine. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in September-October 2012. This report includes data from 16 Data Partners.

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
alosetron HCL
alvimopan
ambrisentan
bosentan
buprenorphine HCL
bupropion HCL
isotretinoin
lenalidomide
metoclopramide HCL
naloxone HCL
nilotinib HCL
propoxyphene HCL
propoxyphene HCL/ASA/caffeine
propoxyphene HCL/acetaminophen
ribavirin/interferon alfa-2B
rosiglitazone/glimepiride
rosiglitazone/metformin HCL
sacrosidase
sibutramine HCL
thalidomide
varenicline tartrate
Time Period
2004 - 2011
Assessment Type
Exploratory Analyses
Study Type
Summary Table
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
CDER
Scroll to Top